Life Science Investing Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma
Life Science Investing Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
Life Science Investing Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
Life Science Investing Bristol Myers Squibb to Participate in Citi's 2025 Global Healthcare Conference
Life Science Investing Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
Life Science Investing Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
Life Science Investing Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
Life Science Investing Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research
Life Science Investing Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025
Life Science Investing Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
